CA
NZ
UK
AU
IND
US
Cytosorbents Corporation's (NASDAQ: CTSO) second-quarter revenue remained flat at $9.6 million compared to the previous year. Analysts had anticipated a slightly better performance, estimating earnings per share of $-0.05, while the actual result showed a net loss of $4.4 million, translating to $0.07 per …
Leef Brands Inc. secured $9.3 million in an oversubscribed financing round, bolstering its balance sheet and providing capacity for future expansions. This strategic move enhances investor confidence, as it positions the company for growth through new acquisitions and market opportunities.Key HighlightsLeef Brands completed an …
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) reported earnings per share (EPS) of $0.91 for the second quarter, a result that comfortably topped the consensus estimate. This performance reflects growing confidence in Amphastar's ability to deliver solid financial results amid a volatile market. With a market …
Verastem Oncology, Inc. (NASDAQ:VSTM) traded up approximately 7.95 percent in pre-market activity, near $6.38 versus Wednesday's close of $5.91. Second quarter net product revenue reached $40.1 million, up sharply from $2.1 million a year earlier, driven by early sales of AVMAPKI FAKZYNJA CO PACK, …
Ardelyx, Inc. (NASDAQ:ARDX) traded down approximately 17.04 percent in pre-market activity, near $4.04 versus Wednesday's close of $4.87, extending a decline that began immediately after the company's after-hours release. Revenue of $118 to $121 million fell short of the $121.6 million consensus, while the …
Halozyme Therapeutics, Inc. (NASDAQ:HALO) traded around $90.00 in pre-market activity, up approximately 4.94 percent from Wednesday's close of $85.76. Total revenue grew 48 percent year over year to $481 million, well ahead of the roughly $404 million consensus, while non-GAAP EPS of $2.28 beat …
Organogenesis Holdings Inc. (NASDAQ:ORGO) traded down approximately 20.12 percent in pre-market activity, near $1.93 versus Wednesday's close of $2.41. Second quarter net product revenue fell 58 percent year over year to $42.8 million, with advanced wound care sales declining 61 percent, even as total …
QuidelOrtho Corporation (NASDAQ:QDEL) traded down approximately 20.34 percent in pre-market activity, near $13.00 versus Wednesday's close of $16.32. Second quarter revenue grew 2 percent to $630.9 million, or nearly 6 percent excluding China, and adjusted EPS of $0.13 beat the $0.04 loss estimate, but …
ResMed Inc. (NYSE:RMD) traded down approximately 7.81 percent before Thursday's open, near $205.80 versus Wednesday's close of $223.24, despite fourth quarter revenue growth of 9 percent to $1.5 billion and non-GAAP EPS of $2.95 topping the $2.90 estimate.
Starling Oncology, Inc. (NASDAQ:STLN), formerly The Oncology Institute, traded up approximately 37.06 percent in pre-market activity to $6.84 versus Wednesday's close of $4.99. The move follows both the company's rebrand, completed earlier this week, and a quarter that beat expectations on multiple fronts.
Please wait processing your request...